Parkinson's disease
Conditions
Interventions
experimental group:FMT with conventional PD therapy
Placebo group:Placebo with conventional PD therapy
Sponsors
Army Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Male and female aged 30 to 85 years; 2) Patients with early Parkinson's disease are definitely diagnosed as having h-y1 ~3 grade of Parkinson's disease in accordance with the diagnostic criteria for Parkinson's disease in China (2016 edition); 3) with normal communication skills; 4) Sign informed consent and agree to participate in this study.
Exclusion criteria
Exclusion criteria: 1) Complicated with other serious diseases of the heart, liver, kidney, respiratory, digestive, blood and endocrine systems; 2) Combined with intestinal double infection, such as CDI, ehec, salmonella, shigella, campylobacter, plague, and cytomegalovirus; 3) Liver function was significantly abnormal or had the following liver disease history: AST or ALT was twice higher than the upper limit of normal value, history of liver cirrhosis, hepatic encephalopathy, history of esophageal varicose veins or portal shunt; 4) With evidence of renal damage or the following renal disease history: serum creatinine is 1.5 times higher than the upper limit of normal value;The history of dialysis;Or a history of nephrotic syndrome; 5) Patients with various acute infections, tumors and severe arrhythmias, mental disorders, drug or alcohol addiction ; 6) Pregnant or lactating women; 7) Have used antibiotics or microecological agents in the past 4 weeks; 8) Patients with allergy or contraindications to "enterobacteria capsule" used in this study; 9) Clinical researchers with other related Parkinson's disease were being conducted at the time of enrollment or within 3 months before enrollment; 10) It is difficult to complete the interview, or various factors affecting the compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| UPDRS scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| IBS-SSS;Gastrointestinal Symptom Rating Scale;BRISTOL stool form scale;IBS-QOL;UPDRS scale;The change of gut microbiota after intervention;PHQ-9 scale;GDS-15 scale;GAD-7 scale;Montreal Cognitive Assessment;Mini-mental State Examination;Adverse effect; | — |
Countries
China
Contacts
Public ContactDongFeng Chen
Army Medical Center
Outcome results
None listed